Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd (Nasdaq: CMMB) will announce its third quarter 2022 financial results on November 11, 2022, at 8:00 am Eastern Time. The event will include a review of performance, recent developments, and a live Q&A session. The company is focused on developing therapeutics for fibrotic and inflammatory diseases, with its lead product, CM-101, in Phase 2 trials for conditions including liver fibrosis. A replay of the call will be available on the company’s website for 90 days following the event.
- Upcoming report of third quarter 2022 financial results on November 11, 2022.
- CM-101 is in Phase 2 trials for significant conditions, demonstrating ongoing developmental progress.
- None.
TEL AVIV, Israel, Nov. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its third quarter 2022 financial results and provide a business update on Friday, November 11, 2022 at 8:00 am Eastern Time.
During the event, Chemomab's management team will review third quarter 2022 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.
A replay of the call will be available on Chemomab's website for 90 days at www.chemomab.com.
Click this Webcast link to access the live webcast or replay.
The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events.
US Investors: +1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference Passcode: 13732524
Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.
Chemomab is a clinical stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to open around year-end, with first patients enrolled in early 2023. For more information, visit chemomab.com.
Contacts:
Investor Relations: | Media: | |
Irina Koffler | Barbara Lindheim | |
LifeSci Advisors, LLC | Chemomab Therapeutics | |
Phone: +1 (917) 734-7387 | Consulting Vice President | |
Investor & Public Relations, | ||
Strategic Communications | ||
Phone: +1 (917) 355-9234 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-report-third-quarter-2022-financial-results-and-provide-a-business-update-301664205.html
SOURCE Chemomab Therapeutics, Ltd.
FAQ
When will Chemomab Therapeutics report its third quarter 2022 financial results?
What is the focus of Chemomab Therapeutics?
What is the status of Chemomab's lead product, CM-101?
Will there be a Q&A session during Chemomab's financial results call?
